CD20 peptides elicit a protective anti -tumor immune response in vivo

被引：0
|
作者：
Teillaud, Jean-Luc [1 ,2 ,3 ,4 ]
Riller, Quentin [1 ,2 ,4 ]
Siberil, Sophie [1 ,2 ,4 ]
机构：
[1] INSERM, UMRS 1138, Paris, France
[2] Cordeliers Res Ctr, Paris, France
[3] Univ Paris 05, Paris, France
[4] Univ Paris 06, Paris, France
来源：
JOURNAL OF IMMUNOLOGY | 2015年 / 194卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
VAC5P.1126
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Anti CD20 (Rituximab) therapy in refractory pediatric rheumatic diseases
    Reis, J.
    Aguiar, F.
    Brito, I
    ACTA REUMATOLOGICA PORTUGUESA, 2016, 41 (01): : 45 - 55
  • [32] Synthetic tumor-specific antigenic peptides with a strong affinity to HLA-A2 elicit anti-breast cancer immune response through activating CD8+ T cells
    Shi, Wei
    Qiu, Qianqian
    Tong, Zhenzhen
    Guo, Weiwei
    Zou, Feng
    Feng, Ziying
    Wang, Yao
    Huang, Wenlong
    Qian, Hai
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2020, 189
  • [33] Tumor treating fields (TTFields) elicit an anti-tumor immune response and in combination enhance anti-PD-1 treatment efficacy
    Kaynan, Noa
    Voloshin, Tali
    Davidi, Shiri
    Porat, Yaara
    Shteingauz, Anna
    Munster, Mijal
    Schneiderman, Rosa
    Giladi, Moshe
    Weinberg, Uri
    Palti, Yoram
    CANCER RESEARCH, 2020, 80 (16)
  • [34] Redistribution of CD20 and Fcγ receptor IIb (CD32b) into lipid rafts is important for internalisation of CD20 upon ligation with type I anti-CD20 mAbs
    Vaughan, A. T.
    Lim, S. H.
    Beers, S. A.
    Glennie, M. J.
    Cragg, M. S.
    IMMUNOLOGY, 2011, 135 : 189 - 189
  • [35] In vivo secreted vesicles allow improvement of anti-tumor immune response
    Thery, Clotilde
    Ostrowski, Matias
    Zeelenberg, Ingrid S.
    M S-MEDECINE SCIENCES, 2008, 24 (6-7): : 581 - 583
  • [36] Surface Levels of CD20 Determine Anti-CD20 Antibodies Mediated Cell Death In Vitro
    Singh, Vijay
    Gupta, Damodar
    Arora, Rajesh
    Tripathi, Rajendra Prashad
    Almasan, Alexandru
    Macklis, Roger M.
    PLOS ONE, 2014, 9 (11):
  • [37] Denintuzumab Mafodotin Stimulates Immune Responses and Synergizes with CD20 Antibodies to Heighten Anti-Tumor Activity in Preclinical Models of Non-Hodgkin Lymphoma
    Van Epps, Heather A.
    Heiser, Ryan
    Cao, Anthony
    Klussman, Kerry
    Yu, Changpu
    Stone, Ivan
    Neale, Jason
    Gardai, Shyra J.
    Law, Che-Leung
    Ryan, Maureen C.
    BLOOD, 2016, 128 (22)
  • [38] Short term in vivo activity of Rituximab anti CD20 monoclonal antibody in B-CLL patients.
    Berchem, GJ
    Heintz, D
    Bosseler, M
    Duhem, C
    Ries, F
    Dicato, MA
    BLOOD, 1999, 94 (10) : 307B - 307B
  • [39] Self-polymerizing Zfra peptides elicit immune response for targeting cancer
    Su, Won-Pei
    Lee, Ming-Hui
    Lin, Sing-Ru
    Chang, Jean-Yun
    Chang, Nan-Shan
    FASEB JOURNAL, 2012, 26
  • [40] Evaluation of CYCLON as a predictive biomarker of anti CD20 response in diffuse large B-Cell lymphoma
    Bouroumeau, A.
    Bussot, L.
    Bonnefoix, T.
    Callanan, M.
    Gressin, R.
    Emadali, A.
    Sartelet, H.
    VIRCHOWS ARCHIV, 2019, 475 : S338 - S338
12345